Lipella Pharmaceuticals Faces Delisting Concerns

TL;DR

Lipella Pharmaceuticals might be delisted, check their listing status.

AI Summary

Lipella Pharmaceuticals Inc. filed an 8-K on January 13, 2025, reporting a notice of delisting or failure to satisfy a continued listing rule. The company's principal executive office is located at 7800 Susquehanna St., Suite 505, Pittsburgh, PA 15208.

Why It Matters

This filing indicates potential issues with Lipella Pharmaceuticals' continued listing on an exchange, which could impact its stock trading and investor confidence.

Risk Assessment

Risk Level: high — A notice of delisting directly threatens the company's ability to remain publicly traded, posing a significant risk to investors.

Key Players & Entities

• Lipella Pharmaceuticals Inc. (company) — Registrant
• January 10, 2025 (date) — Earliest event reported
• January 13, 2025 (date) — Date of report
• 7800 Susquehanna St., Suite 505, Pittsburgh, PA 15208 (location) — Principal executive office address

FAQ

Key Financial Figures

• $0.0001 — registered Common Stock, par value $0.0001 per share LIPO The Nasdaq Stock Mar

Filing Documents

• g084656_8k.htm (8-K) — 36KB
• 0001753926-25-000078.txt ( ) — 208KB
• lipo-20250110.xsd (EX-101.SCH) — 3KB
• lipo-20250110_lab.xml (EX-101.LAB) — 33KB
• lipo-20250110_pre.xml (EX-101.PRE) — 22KB
• g084656_8k_htm.xml (XML) — 4KB

01

Item 3.01. Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On January 10, 2025, Lipella Pharmaceuticals Inc. (the "Company") received a decision (the "January Letter") from the Nasdaq Hearings Panel (the "Panel") of The Nasdaq Stock Market LLC ("Nasdaq") granting the Company's request for continued listing on the Nasdaq Capital Market, subject to the Company demonstrating compliance with Nasdaq Listing Rule 5550(b)(1) (the "Minimum Stockholders' Equity Requirement"), including the achievement of interim milestones. Specifically, the Panel granted the Company's request for continued listing, subject to the following: (i) on or before April 14, 2025, the Company must file a public disclosure describing any transactions undertaken by the Company to increase its equity and providing an indication of its equity following those transactions; and (ii) on or before April 14, 2025, the Company must provide the Panel with an update on its fundraising plans, updated income projections for the next 12 months, with all underlying assumptions clearly stated, and a description of how the Company intends to achieve, if necessary, and maintain compliance with Nasdaq Listing Rule 5550(a)(2) (the "Minimum Bid Price Requirement"). It is the Company's intention to comply with conditions (i) and (ii) listed in the January Letter as well as to demonstrate compliance with the Minimum Stockholders' Equity Requirement on or before April 14, 2025. There can be no assurance that the Company will be able to comply with all of the obligations placed on us by the Panel pursuant to the January Letter, and, assuming that we are able to comply with such obligations, that we will be able to continue to comply with other continued listing standards of Nasdaq in the future, including the Minimum Bid Price Requirement. If we fail to meet all of the conditions listed in the January Letter, our common stock, par value $0.0001 per share (the "Co

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: January 13, 2025 Lipella Pharmaceuticals Inc. By: /s/ Jonathan Kaufman Name: Jonathan Kaufman Title: Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR